![home-bg-image.jpg](https://media.scintomics.com/1e79e7f0-1824-4bef-9e20-d7a321009ef4/82522f64-905d-4f5a-a75b-c5c2d4a54f01.jpg?nearlossless=1)
![PentixaPharm thumbnail news.jpg](https://media.scintomics.com/1e79e7f0-1824-4bef-9e20-d7a321009ef4/e913252a-31d1-4c55-a77c-9a7fc3012b9e.jpg?nearlossless=1)
Scintomics and 1717 Life Science Ventures Team up
Scintomics and 1717 LSV to collaborate in the development of novel cancer diagnostics and treatment.
Read more![Blue-Earth logo 900400.jpg](https://media.scintomics.com/1e79e7f0-1824-4bef-9e20-d7a321009ef4/6634a5f7-b7f8-4eff-9441-ac8db7123c56.jpg?nearlossless=1)
Blue Earth Diagnostics Expands Oncology Portfolio with Exclusive, Worldwide Licensing of Investigational Radiohybrid PSMA-targeted Agents for Prostate Cancer from Scintomics
Blue Earth Diagnostics has acquired the exclusive worldwide rights to a broad family of Prostate Specific Membrane Antigen (PSMA)-targeted radiohybrid (“rh”) agents for cancer imaging, together with an exclusive option to explore therapeutic applications.
Read more- 1
- 2